Table 2 FDA-approved drugs with signatures discordant to the signatures of AP-naive FEP and early dysglycemia.

From: Glucose dysregulation in antipsychotic-naive first-episode psychosis: in silico exploration of gene expression signatures

Perturbagen

Canonical Mechanism of Action

Anatomical Therapeutic Chemical First Level Classification

Studies in PSDs

Chlorpropamide

Bind to ATP-sensitive potassium channels on pancreas, leading to insulin secretion

Alimentary tract and metabolism

-

Clobetasol

Bind to glucocorticoid receptors

Dermatologicals

-

Daunorubicin

DNA topoisomerase inhibitor

Antineoplastic and immunomodulating agents

-

Flunisolide

Glucocorticoid receptor agonist

Respiratory system

-

Irinotecan

DNA topoisomerase inhibitor

Antineoplastic and immunomodulating agents

-

Medrysone

Glucocorticoid receptor agonist

Sensory Organs

-

Mestranol

Estrogen receptor agonist

Not available

-

Metformin

Inhibits mitohcondrial complex 1 in the liver

Alimentary tract and metabolism

de Silva et al., 2016; Siskind et al., 2016; Praharaj et al., 2011

Tamoxifen

Estrogen receptor competitive inhibitor; protein Kinase C inhibitor; sex hormone-binding globulin inducer

Antineoplastic and immunomodulating agents

-

  1. The canonical mechanism of action was referenced from DrugBank (https://go.drugbank.com/) and the classification from Anatomical Therapeutic Chemical (https://www.whocc.no/atc_ddd_index/). Studies examining these agents as a potential therapeutic for psychopathology or metabolic dysfunction in PSDs are indicated on the right.
  2. AP-naive FEP antipsychotic-naive first-episode psychosis, PSDs psychosis spectrum disorders
Back to article page